Evidence map›Paper›PMID 40483626›Full record

ArticleInfection2025

Clostridioides difficile evolution in a tertiary German hospital through a retrospective genomic characterization.

Fabian Lorenzo-Diaz, Tilman E Klassert, Cristina Zubiria-Barrera, Amelya Keles-Slevogt, Mario Gonzalez-Carracedo, Mariano Hernandez, Hortense Slevogt, Thomas Grünewald

Abstract read
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fabian Lorenzo-Diaz *Genomics and Health Group, Departamento de Bioquímica, Microbiología, Biología Celular y Genética, Facultad de Ciencias, Canary Islands, Universidad de La Laguna, La Laguna, Spain. florenzo@ull.edu.es.
Tilman E Klassert *Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, German Centre for Lung Research (DZL), BREATH, Hannover, Germany.
Cristina Zubiria-BarreraDepartment of Respiratory Medicine and Infectious Diseases, Hannover Medical School, German Centre for Lung Research (DZL), BREATH, Hannover, Germany.
Amelya Keles-SlevogtDepartment of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Mario Gonzalez-CarracedoGenomics and Health Group, Departamento de Bioquímica, Microbiología, Biología Celular y Genética, Facultad de Ciencias, Canary Islands, Universidad de La Laguna, La Laguna, Spain.
Mariano HernandezGenomics and Health Group, Departamento de Bioquímica, Microbiología, Biología Celular y Genética, Facultad de Ciencias, Canary Islands, Universidad de La Laguna, La Laguna, Spain.
Hortense SlevogtDepartment of Respiratory Medicine and Infectious Diseases, Hannover Medical School, German Centre for Lung Research (DZL), BREATH, Hannover, Germany.
Thomas GrünewaldClinic for Infectious Diseases and Tropical Medicine, Klinikum Chemnitz, Chemnitz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClostridioides difficile is a major cause of healthcare-associated infections, contributing to significant morbidity and mortality. This study aimed to investigate the genomic characteristics, antimicrobial resistance (AMR) profiles, and temporal dynamics of C. difficile strains isolated from hospitalized patients in a German tertiary hospital over nearly two decades (1997-2015).

methodsWhole-genome sequencing was performed on 46 toxigenic C. difficile isolates to determine sequence types (STs) and phylogenetic relationships and these were compared to national surveillance data on C. dificile. AMR profiling was conducted to identify key resistance determinants at genetic level while epsilometer minimum inhibitory concentration (MIC) analyses were used to correlate genetic resistance markers with phenotypic resistance. Longitudinal antibiotic usage data were analysed to assess potential associations with resistance profiles and strains evolution.

resultsFive predominant STs were identified: ST1 (30%), ST54 (24%), ST3 (22%), ST11 (11%), and ST37 (4%). Phylogenetic analysis showed that ST1 (ribotype 027) emerged as the dominant and persistent lineage, replacing ST11 and ST54 over time. AMR profiling detected several resistance genetic markers such as CDD-1/CDD-2 (carbapenem resistance), ErmB (macrolide-lincosamide-streptogramin B resistance/MLS resistance), and mutations in gyrA (fluoroquinolone resistance) and rpoB (rifampicin resistance). MIC analyses confirmed high resistance rates to moxifloxacin (87%) and rifampicin (59%), while susceptibility to fidaxomicin, metronidazole, and vancomycin remained. The tetM gene, associated with doxycycline resistance, declined as ST11 and ST54 frequencies decreased. Longitudinal analysis revealed a reduction in moxifloxacin resistance following its decreased use, whereas increased doxycycline use paradoxically correlated with reduced resistance.

conclusionThis study highlights the dynamic strain evolution of C. difficile, reflecting national trends in strain evolution. The findings emphasize the strong correlation between epsilometer MIC values and molecular resistance markers. This observation reinforces the integration of genetic surveillance with antibiotic stewardship in the clinical routine to effectively mitigate CDI recurrence. Further research is needed to better understand the complex interactions between antibiotic exposure and strain evolution in hospital environments.

Indexed as

Clostridioides difficileClostridium InfectionsAnti-Bacterial AgentsCross InfectionDrug Resistance, BacterialEvolution, MolecularFemaleGenome, BacterialGermanyHumansMaleMicrobial Sensitivity TestsPhylogenyRetrospective StudiesTertiary Care CentersWhole Genome SequencingAnti-Bacterial AgentsAntibiotic resistance genesCDIClostridioides difficilePaLocWGS

Identifiers

PMID40483626
PMCPMC12460453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.